209 related articles for article (PubMed ID: 30529752)
1. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas.
Leijon H; Remes S; Hagström J; Louhimo J; Mäenpää H; Schalin-Jäntti C; Miettinen M; Haglund C; Arola J
Hum Pathol; 2019 Apr; 86():66-75. PubMed ID: 30529752
[TBL] [Abstract][Full Text] [Related]
2. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas.
Elston MS; Meyer-Rochow GY; Conaglen HM; Clarkson A; Clifton-Bligh RJ; Conaglen JV; Gill AJ
Hum Pathol; 2015 Mar; 46(3):390-6. PubMed ID: 25554089
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
4. Warburg effect's manifestation in aggressive pheochromocytomas and paragangliomas: insights from a mouse cell model applied to human tumor tissue.
Fliedner SM; Kaludercic N; Jiang XS; Hansikova H; Hajkova Z; Sladkova J; Limpuangthip A; Backlund PS; Wesley R; Martiniova L; Jochmanova I; Lendvai NK; Breza J; Yergey AL; Paolocci N; Tischler AS; Zeman J; Porter FD; Lehnert H; Pacak K
PLoS One; 2012; 7(7):e40949. PubMed ID: 22859959
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.
Patel M; Tena I; Jha A; Taieb D; Pacak K
Front Endocrinol (Lausanne); 2021; 12():625312. PubMed ID: 33854479
[TBL] [Abstract][Full Text] [Related]
6. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Turkova H; Prodanov T; Maly M; Martucci V; Adams K; Widimsky J; Chen CC; Ling A; Kebebew E; Stratakis CA; Fojo T; Pacak K
Endocr Pract; 2016 Mar; 22(3):302-14. PubMed ID: 26523625
[TBL] [Abstract][Full Text] [Related]
7. N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease.
Leijon H; Kaprio T; Heiskanen A; Satomaa T; Hiltunen JO; Miettinen MM; Arola J; Haglund C
J Clin Endocrinol Metab; 2017 Nov; 102(11):3990-4000. PubMed ID: 28938401
[TBL] [Abstract][Full Text] [Related]
8. Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma.
Rao JU; Engelke UF; Rodenburg RJ; Wevers RA; Pacak K; Eisenhofer G; Qin N; Kusters B; Goudswaard AG; Lenders JW; Hermus AR; Mensenkamp AR; Kunst HP; Sweep FC; Timmers HJ
Clin Cancer Res; 2013 Jul; 19(14):3787-95. PubMed ID: 23723300
[TBL] [Abstract][Full Text] [Related]
9. Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.
Saveanu A; Muresan M; De Micco C; Taieb D; Germanetti AL; Sebag F; Henry JF; Brunaud L; Enjalbert A; Weryha G; Barlier A
Endocr Relat Cancer; 2011 Apr; 18(2):287-300. PubMed ID: 21335363
[TBL] [Abstract][Full Text] [Related]
10. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
[TBL] [Abstract][Full Text] [Related]
11. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
[TBL] [Abstract][Full Text] [Related]
12. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis.
Kumar U; Sasi R; Suresh S; Patel A; Thangaraju M; Metrakos P; Patel SC; Patel YC
Diabetes; 1999 Jan; 48(1):77-85. PubMed ID: 9892225
[TBL] [Abstract][Full Text] [Related]
13. A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy.
Pacak K; Kidd M; Meuter L; Modlin IM
Endocr Relat Cancer; 2021 Oct; 28(11):731-744. PubMed ID: 34515661
[TBL] [Abstract][Full Text] [Related]
14. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
15. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
[TBL] [Abstract][Full Text] [Related]
16. [Somatostatin receptors expression (SSTR1-SSTR5) in pheochromocytomas].
Hubalewska-Dydejczyk A; Trofimiuk M; Sowa-Staszczak A; Gilis-Januszewska A; Wierzchowski W; Pach D; Budzyński A; Karcz D
Przegl Lek; 2008; 65(9):405-7. PubMed ID: 19140390
[TBL] [Abstract][Full Text] [Related]
17. Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism.
Tevosian SG; Ghayee HK
J Clin Endocrinol Metab; 2018 May; 103(5):1779-1789. PubMed ID: 29409060
[TBL] [Abstract][Full Text] [Related]
18. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.
Kumar U; Grigorakis SI; Watt HL; Sasi R; Snell L; Watson P; Chaudhari S
Breast Cancer Res Treat; 2005 Jul; 92(2):175-86. PubMed ID: 15986128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
